Filing Details

Accession Number:
0000899243-23-009600
Form Type:
4/A
Zero Holdings:
No
Publication Time:
2023-03-24 18:45:03
Reporting Period:
2023-03-16
Accepted Time:
2023-03-24 18:45:03
Original Submission Date:
2023-03-20
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1658551 Amylyx Pharmaceuticals Inc. AMLX () 4/A
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1358266 D Patrick Yeramian C/O Amylyx Pharmaceuticals, Inc.
43 Thorndike Street
Cambridge MA 02141
Chief Medical Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2023-03-16 2,789 $0.33 207,088 No 4 M Direct
Common Stock Acquisiton 2023-03-16 30,041 $0.37 237,129 No 4 M Direct
Common Stock Acquisiton 2023-03-16 16,748 $6.88 253,877 No 4 M Direct
Common Stock Disposition 2023-03-16 52,211 $31.85 201,666 No 4 S Direct
Common Stock Disposition 2023-03-16 2,416 $32.43 199,250 No 4 S Direct
Common Stock Acquisiton 2023-03-16 9,167 $0.00 208,417 No 4 A Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 M Direct
No 4 S Direct
No 4 S Direct
No 4 A Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (right to buy) Acquisiton 2023-03-16 41,250 $0.00 41,250 $32.08
Common Stock Stock Option (right to buy) Disposition 2023-03-16 2,789 $0.00 2,789 $0.33
Common Stock Stock Option (right to buy) Disposition 2023-03-16 30,041 $0.00 30,041 $0.37
Common Stock Stock Option (right to buy) Disposition 2023-03-16 16,748 $0.00 16,748 $6.88
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
41,250 2033-03-16 No 4 A Direct
0 2028-02-16 No 4 M Direct
62,466 2029-03-18 No 4 M Direct
48,252 2031-02-21 No 4 M Direct
Footnotes
  1. On March 16, 2023, the Reporting Person filed a Form 4 (the "Original Form 4") which inadvertently omitted the exercise of an aggregate of 49,578 options by the Reporting Person. The Original Form 4 reported the sale of shares of Common Stock of the Issuer ("Common Stock") underlying those options, pursuant to a Rule 10b5-1 trading plan. This Form 4 amendment is being filed for the purpose of amending and restating the Original Form 4 solely to report the exercise of the stock options and the resulting increase in beneficial ownership of Common Stock. The Reporting Person has not sold any additional shares of Common Stock beyond those sales reported in the Original Form 4.
  2. These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 14, 2022.
  3. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $31.26 to $32.25. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
  4. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $32.28 to $32.93. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
  5. The reported transaction involves the Reporting Person's receipt of a restricted stock unit award (a "RSU"). The RSU shall vest in 4 equal annual installments, with the first installment vesting on the first day of the month of the one year anniversary of the date of grant, subject to the Reporting Person's continued service to the Issuer through such vesting date.
  6. 1/4 of the shares subject to the option shall vest and become exercisable on the first day of the month of the one year anniversary of the date of grant, and the remaining shares shall vest monthly over the remaining 36 months, subject to the Reporting Person's continuous service to the Issuer through such vesting date.
  7. The shares subject to such option are vested and currently exercisable.
  8. As of the date of this filing, 39,688 shares subject to the option are vested and exercisable. 52,819 shares subject to such option vest and become exercisable in substantially equal monthly installments until November 26, 2023.
  9. 16,256 shares underlying this option vested on February 19, 2022, with the remaining shares vesting in monthly installments of 1,354 shares thereafter.